eligibility_summary
Eligibility: endometrial carcinoma (incl carcinosarcoma, not uterine sarcoma), 1–4 prior systemic lines (≤2 chemo), incl platinum and anti‑PD‑1/PD‑L1 unless declined/ineligible, progression/intolerance, ECOG 0–1, >6 mo, ≥1 resectable and ≥1 measurable lesion, adequate organs, contraception 12 mo post, >70 allowed. Exclude: symptomatic brain mets, prior allogeneic transplant or cell therapy ≤20y, steroids >10 mg/d, primary immunodeficiency, other cancer ≤3y, live vaccine ≤28d pre‑NMALD.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
manual_review_required
ai_summary
NCT06481592 (Phase 2, single-arm) tests lifileucel, an autologous cellular immunotherapy (tumor-infiltrating lymphocytes, TIL) for advanced endometrial cancer after platinum and PD‑1/PD‑L1 therapy. Regimen: surgical harvest and ex vivo expansion of TILs → non‑myeloablative lymphodepleting chemotherapy (cyclophosphamide + fludarabine, cytotoxic chemotherapies) → lifileucel infusion → high‑dose IL‑2 (cytokine therapy). Mechanisms: polyclonal CD8+/CD4+ TILs recognize patient-specific tumor antigens via TCR–MHC and kill via perforin/granzyme, lymphodepletion removes regulatory/suppressive lymphocytes and creates “space”, IL‑2 drives T‑cell expansion/survival via IL‑2R/STAT5 signaling. Targets: tumor cells and TME, pathways include TCR signaling, IL‑2 signaling, and depletion of Tregs/immune competition.